Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESBA105 in Cataract Surgery and Vitrectomy
NCT00820014Phase 2Completed
- Sponsor
- ESBATech
- Start
- Jan 2009
- Primary completion
- Sep 2010
- Modality
- Antibody Conjugates, scFv Fragments, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of DLX105 in post-operative inflammation, sponsored by ESBATech. Started Jan 2009; status: completed.
02
Drugs
DLX105
03
Conditions
post-operative inflammation
Beyond the preview
Go deeper on NCT00820014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00820014.